Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations-Reference-Cited by-同舟云学术

Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations

Published:2022-11-01 Issue:11 Volume:24 Page:814-823
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Forlenza Gregory P.¹^ORCID,Carlson Anders L.²,Galindo Rodolfo J.³^ORCID,Kruger Davida F.⁴,Levy Carol J.⁵,McGill Janet B.⁶^ORCID,Umpierrez Guillermo⁷,Aleppo Grazia⁸

Affiliation:

1. Barbara Davis Center, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.

2. International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA.

3. Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, Georgia, USA.

4. Division of Endocrinology, Diabetes, Bone and Mineral, Henry Ford Health System, Detroit, Michigan, USA.

5. Division of Endocrinology, Diabetes, and Metabolism, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

6. Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis, Missouri, USA.

7. Division of Endocrinology, Metabolism Emory University School of Medicine, Atlanta, Georgia, USA.

8. Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2022.0206

Reference33 articles.

1. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes

2. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes

3. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology

4. Efficacy of Artificial Pancreas Use in Patients With Type 2 Diabetes Using Intensive Insulin Therapy: A Randomized Crossover Pilot Trial

5. Real-world Performance of the MiniMed™ 780G System: First Report of Outcomes from 4’120 Users

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Evidence of Omnipod^® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes;Diabetes Technology & Therapeutics;2024-08-01

2. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1‐year real‐world assessment;Diabetes, Obesity and Metabolism;2024-07-15

3. Real‐world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta‐analysis;Diabetes, Obesity and Metabolism;2024-06-18

4. Neural-Net Artificial Pancreas: A Randomized Crossover Trial of a First-in-Class Automated Insulin Delivery Algorithm;Diabetes Technology & Therapeutics;2024-06-01

5. Diabetes Technology in the “Real World”: Expanding Access and Addressing Disparities;Diabetes Technology & Therapeutics;2024-03-01